StockWireNews

(EVAHF) Dropped Big News Friday, Is A Low Float Profile To Watch Closely Tomorrow AM

U.S. OTC: (EHAVF) - Canada CSE: (TMED)

June 27th

Good Evening,

Psi-loc-ybin is one of the most effective psych-e-delics for the treatment of conditions such as treatment-resistant depression, anxiety, PTSD and depression.

These natural benefits, known for years to traditional societies, are only now being researched after decades of stigmatization and inaccurate scaremongering.

The world’s leading academic institutions are compiling a growing amount of research into the benefits of psi-lo-cybin.

Universities such as Imperial College London, the NYU Grossman School of Medicine and Johns Hopkins University, and medical research bodies including the Heffter Research Institute, the Beckley Foundation and MAPS have all contributed to this.

But, let's dive in a little deeper...

Mental Health - Key Statistics To Know Now

Take a breath and try to wrap your head around this (Sources 1 & 2):

• 25% - Global population with mental health/neurological disorders
• 450M - People with inadequate first-line treatment options
• 75% - Of people with serious substance abuse with inadequate treatment
• $10B - Current global market for DPS treatment
• $128.9Bn - Projected global market for mental health/neurological disorders in 2025
• 1 in 11 - People will suffer from PTSD at some point in their lives

Let's face it, these figures are unacceptable.

To try and combat these mental health issues, there's one company flying under Wall Street's radar that may turn out to be a true game-changer in the space.

For Monday, June 28th, there is only one profile to have at the top of your watch-list:

EGF Theramed Health Corp. (EVAHF)

EGF Theramed Health is positioning itself at the frontier of medical science.

Psych-e-delic dr-ugs are gathering support as a bona fide treatment for mental health problems, one of the most pressing and costly crises facing the modern world.

EVAHF is exploring every opportunity on offer in this new area of research, forming partnerships with pioneering companies.

Their current focus is on the psil-o-cybin space, looking at methods of improving delivery systems for the compound, and creating strong intellectual property.

The company explores many other medical areas including weight loss, skin care and heart disease.

EGF Theramed Health Corp. also trades on the Canadian Securities Exchange under the symbol (CSE: TMED).

EVAHF Portfolio: Pharmadelic Labs & Green Parrot Labs

Pharmadelic Labs

On May 6th, 2020, Theramed acquired a 30% stake in Pharmadelic Labs.

Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds - primarily psi-lo-cybin, the psych-o-active component of magic mush-rooms.

Now, leading scientists, academic institutions and government administrations are turning their attention to the benefits of psi-lo-cybin as a potential treatment for the global problems of mental health and end of life care. The ability to produce this molecule quickly, economically and cleanly, as Pharmadelic Labs is aiming to achieve, will be in high demand when psi-loc-ybin gains widespread acceptance.

-----

Green Parrot Labs

On May 22nd, 2020, EGF Theramed acquired a 40% stake in Green Parrot Labs.

Green Parrot Labs is a company with operations based in the Caribbean, offering wellness centers and research and development into biosynthesis pathways for psi-lo-cybin and cann-a-binoids.

The two operations of the company take advantage of the generous laws in Barbados, Jamaica and the British Virgin Islands towards medical tourism and research into rare compounds.

Green Parrot will be offering services providing a tailored treatment program for individuals suffering from inflammatory bowel disease (IBD) in specialized wellness centers.

The research and development facilities will be aimed at producing biosynthesis pathways that can be licensed across the world, and used in the wellness centers.

-----

And, right now, this profile has multiple potential driver indicators that could signal an upcoming vertical move on the horizon.

None may be bigger than Friday afternoon's huge news. Check it out.

Top Potential Driver Indicator - Pharmadelic Labs Signs Services Agreement

EGF Theramed Joint Venture Partner Pharmadelic Labs Announces Lab Services Agreement With Numinus Wellness

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) ("Theramed", the "Company") is pleased to announce that its subsidiary joint venture Pharmadelic Labs Inc. ("Pharmadelic") has signed a laboratory services agreement with Numinus Wellness Inc. (TSXV: NUMI) ("Numinus").

Pharmadelic is a biotech company focused on developing, improving and patenting engineering processes for the biosynthesis of compounds, primarily psi-lo-cybin. Through the Health Canada-licensed Numinus Bioscience lab in British Columbia, Canada, Numinus will provide Pharmadelic with lab expertise and R&D services such as analytical, purity and compound identification testing along with regulatory and compliance consulting services.

Pharmadelic aims to develop a portfolio of intellectual property around biosynthesis pathways using yeast and psi-lo-cybin. By editing the genome sequences of industrial brewing yeasts, the company plans to create commercially viable compounds derived from psi-lo-cybin. The expected advantages of this method include:

• significantly quicker than growing and extracting from mush-rooms (days rather than weeks)
• safe, through the use of GRAS (Generally Recognized As Safe) products ready for use in industry
• a controlled and uniform level of psi-lo-cybin throughout the finished product
• much cheaper to produce on a mass scale than greenhouse growing

"The agreement with Numinus accelerates and expands Pharmadelic's ability to produce valuable intellectual property and increase shareholder value for both Pharmadelic and TMED," said George Anstey, CEO of Pharmadelic Labs Corp and director of EGF Theramed. "We look forward to working with Numinus to drive our R&D agenda and create and support the advancement of health and wellness for all."

Pharmadelic will work with a wide range of partners across multiple industries, starting with pharmaceutical companies creating products for the nascent psych-e-delics market.Under Canada's Controlled Dr-ugs and Substances Act, Numinus Bioscience can possess, produce, assemble, sell, export, and deliver a wide variety of psych-e-delics...[...].

The laboratory provides internationally acclaimed analytical and natural product chemists, biochemists, molecular biologists and quality management experts, state-of-the-art equipment and proprietary methods to ensure validated results and finished products.

The specific terms of the two-year agreement are private. Numinus Wellness has taken an equity position in Pharmadelic. The agreement was signed May 28, 2021. The agreement is subject to certain requirements.

Read the full article here.

-----

Potential Driver Indicator - Explosive Chart History

Just take a look at EVAHF's 1-year chart:

Do you see what I see?

I see a profile that has displayed the ability to make a major breakout in the blink of an eye.

Back at the beginning of December 2020, this profile was trading around the same level that it is at currently.

But, back then, something special happened.

From a low on 12/8/20, EVAHF dropped to a low of $.0522. By the time 12/15/20 came around, this profile had surged all the way to a high of $.2803.

In roughly 1 week, EVAHF had rocketed 436%!

Yup. You're reading that correctly. 436%.

Now, with this profile trading around $.06-$.08 range, could its next major run be right around the corner?

If Thursday was any indication, all eyes may be on EVAHF at the moment.

Huge Volume Breakout - Another Potential Driver Indicator

On Thursday, EVAHF saw way above average daily trading volume.

You have to go back to 5/19/21, over a month ago, to find a day in which EVAHF saw as much volume in a single day.

That day the profile shot roughly 57% and nearly $.04 from its open to its high.

We saw the same kind of bump Thursday when EVAHF jumped almost $.02 and 31% intraday.

A 3rd Potential EVAHF Driver Indicator - Float Under 23Mn

According to OTCMarkets, here is EVAHF's float.

This could lead to some pretty volatile trading if Wall Street continues to uncover the company.

And, as I just mentioned above, this profile has shown the ability to make strong double-digit surges in the blink of an eye.

Plus, volatility could pop up as the law of supply and demand takes place while the world learns more about medicinal mush-rooms and their potential with big pharma.

Let's dig in further...

Agreement To Acquire Seedadelic Med Corp. - A 4th Potential Driver Indicator

EGF Theramed Signs Agreement to Acquire Seedadelic Med Corp.

VANCOUVER, BC / ACCESSWIRE / December 14, 2020 / EGF Theramed Health Corp. (CSE:TMED)(OTCQB:EVAHF)(FSE:AUHP) (the "Company") is pleased to announce that the Company has entered into a letter of intent dated as of December 14, 2020 to acquire all of the issued and outstanding shares of Seedadelic Med Corp. ("Seedadelic"), a private Ontario corporation) in exchange for the issuance of 15,000,000 common shares of the Company at a deemed price of $0.115 per common share to Seedadelic shareholders (the "Proposed Transaction"). The Company has also agreed to pay a finder's fee on the closing of the Proposed Transaction.)

The Proposed Transaction will provide the Company with ownership of Seedadelic, a seedbank holding consisting of L-S-A and psych-e-delic properties. L-S-A is a legal alternative to L-S-D consisting of similar properties and effects of D-lyser-gic ac-id diethyl-amide but with less side effects. Seedbank will allow the Company to market and commercialize in a LGL and rapid pace.

"We are incredibly pleased to be on the forefront of psych-e-delic technology. L-S-A is an underutilized and very rarely recognized compared to its alternative L-S-D. We feel there is a significant gap in the market that we can fill with L-S-A products and its properties," stated Jatinder Dhaliwal - Chief Executive Officer of the Company.

Readers are cautioned that the final terms and structure for the Proposed Transaction have not yet been determined. Completion of the Proposed Transaction remains subject to the negotiation of definitive documentation, completion of customary due diligence and receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied. The Company will provide additional information regarding the Proposed Transaction as soon as it becomes available.

Read the full article here.

-----

If this LOI turns into a complete transaction in the near future, it could act as a major catalyst.

EVAHF Recap - 5 Potential Driver Indicators

#1. Pharmadelic Labs Signs Services Agreement

#2. Breakout Chart History

#3. Recent Above Average Trading Volume

#4. Low Float Under 23Mn Shares

#5. Entering Into LOI To Acquire Seedadelic

-----

For these reasons, I'm initiating coverage on EVAHF.

While you have some time, do this:

Before Monday's opening bell, get EVAHF on your radar

Sincerely,

Kai Parker

StockWireNews

Source 1
Source 2

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)